CUE (Cue Biopharma, Inc.) Stock Analysis - AI Report

Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of May 21, 2026, CUE trades at $20.03 with a market cap of $86.50M and a P/E ratio of -16.45. CUE moved -1.53% today. Year to date, CUE is +77.99%; over the trailing twelve months it is +1.70%. Its 52-week range spans $4.97 to $59.67. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on CUE?

Rallies AI research for CUE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

CUE Key Metrics

Key financial metrics for CUE
MetricValue
Price$20.03
Market Cap$86.50M
P/E Ratio-16.45
EPS$-1.21
Dividend Yield0.00%
52-Week High$59.67
52-Week Low$4.97
Volume385
Avg Volume0
Revenue (TTM)$32.73M
Net Income$-19.52M
Gross Margin0.00%

Latest CUE News

Recent CUE Insider Trades

  • Sarraf Pasha bought 4.23K (~$1.31K) on Dec 30, 2025.
  • Sarraf Pasha bought 77.15K (~$23.17K) on Dec 30, 2025.
  • Sarraf Pasha bought 86.95K (~$27.60K) on Dec 30, 2025.

CUE Analyst Consensus

CUE analyst coverage data. Average price target: $0.00.

Common questions about CUE

What is the AI research view on CUE?
Rallies AI research for CUE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for CUE?
Rallies AI research for CUE combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is CUE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.
CUE

CUE